26.05.2005 07:00:00

PURE. NATURAL. LONG LASTING. PURAGEN DERMAL FILLER LAUNCHED TODAY; Next-generation hyaluronic acid product - the benchmark in consumer cosmetic choices

PURAGEN(TM), the next-generation dermal fillermanufactured by Mentor, is now available across Europe. This newproduct is a clear gel that is injected to smooth lines, banishwrinkles, plush lips or fill depressions. PURAGEN is the only productwith proprietary DXL(TM) technology, which is designed to providegreater stability over time.

PURAGEN is based on hyaluronic acid, a natural skin componentresponsible for the plumpness and smoothness typical of younger skin.The source of the new product's performance lies in its innovativestructure - only in PURAGEN are hyaluronic acid molecules doublecross-linked to one another. This strengthened bonding providespatients with two key benefits:

-- the gel particles are smaller making the procedure more comfortable

-- the gel particles are designed to survive longer before being absorbed by the skin

"Puragen represents an important advancement for patients andgives a very smooth injection, resulting in a uniform filling to thelips and lower face lines," commented Nicholas Lowe, M.D., a leadingdermatologist and cosmetic surgeon with practices in London, England,and Santa Monica, California. "My European patients are pleased withthe results of the product thus far, which appears to provide a longduration of wrinkle correction."

PURAGEN is a pure form of hyaluronic acid derived from bacterialfermentation and does not have the risks associated with otherproducts derived from animal by-products. PURAGEN is uniquelystabilised through Mentor's patent-protected DXL(TM) technology, whichintroduces two discrete double cross-linking reactions designed toprovide improved product stability relative to all other commerciallyavailable hyaluronic acid based dermal fillers on the market inEurope, Canada and the United States.

About Mentor Corporation

Founded in 1969, Mentor Corporation is a leading supplier ofmedical products for the global healthcare market. The Companydevelops, manufactures and markets innovative, science-based productsfor the aesthetics, urologic specialties and clinical and consumerhealthcare markets around the world. The Company's website iswww.mentorcorp.com

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Analysen zu Johnson & Johnsonmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Johnson & Johnson 138,04 -0,99% Johnson & Johnson

Indizes in diesem Artikel

S&P 600 SmallCap 935,46 -0,94%